You are viewing: UK Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The UK Plasma Fractionation Market was valued at $1471.5 Million in 2026 and projected to reach to $2174.4 Million by 2031, representing a compound annual growth rate of CAGR 8.1%. The UK plasma fractionation market is positioned for sustained growth through 2031, driven by demographic shifts, increased diagnosis rates, and expanding therapeutic indications for plasma-derived products.

UK Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Plasma Fractionation Market Trends and Insights

  • The UK market benefits from advanced healthcare infrastructure, strong regulatory frameworks, and increasing demand for immunoglobulin and clotting factor therapies.
  • The UK's aging population and rising prevalence of immunodeficiency disorders are driving sustained demand for plasma-derived products. In the UK, the plasma fractionation sector is characterized by robust clinical adoption and government support through the NHS.
  • Between 2026 and 2031, the UK market is expected to expand significantly as healthcare providers invest in rare disease treatment and hemophilia management.
  • The UK's commitment to self-sufficiency in plasma collection and the presence of major fractionation facilities position the country as a key player in European plasma therapeutics. The UK plasma fractionation market growth is underpinned by technological advances in purification methods, increased awareness of plasma-dependent conditions, and favorable reimbursement policies.
  • The UK's regulatory environment continues to support innovation while ensuring product safety and efficacy, creating a stable foundation for market expansion through 2031..

Key Market Statistics

  • CAGR (2026-2031) CAGR 8.1%
  • Market Size, 2026 ~USD 1471.5 Million
  • Forecast, 2031 ~USD 2174.4 Million
  • Country UK

UK Plasma Fractionation Market Overview

Market Valuation Growth :

The UK plasma fractionation market is valued at USD 1,471.5 million in 2026 and is projected to reach USD 2,174.4 million by 2031, demonstrating robust expansion at an 8.1% CAGR, outpacing the global average of 7.6%.

Advanced Healthcare Infrastructure :

The UK's well-established NHS framework, coupled with stringent regulatory oversight from the MHRA and EMA, creates a stable environment for plasma-derived therapies and ensures high-quality product standards across immunoglobulins and clotting factors.

Aging Population Dynamics :

With an increasingly aging demographic, the UK faces rising prevalence of immunodeficiency disorders, hemophilia, and thrombotic conditions, driving sustained demand for plasma fractionation products and specialized therapeutic interventions.

Immunoglobulin and Clotting Factor Demand :

Growing clinical adoption of intravenous immunoglobulin (IVIG) therapies and factor replacement treatments in UK hospitals and specialty clinics reflects expanding therapeutic applications and improved patient access to life-saving plasma-derived medicines.

UK Plasma Fractionation Market Dynamics

  • The NHS's commitment to rare disease management and improved reimbursement pathways for immunoglobulin therapies will support market expansion.
  • Additionally, investments in domestic plasma collection infrastructure and regulatory support for novel fractionation technologies will enhance supply chain resilience and reduce import dependency, further strengthening market dynamics across immunology, hematology, and critical care segments..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • The UK plasma fractionation market will grow from USD 1,471.5M (2026) to USD 2,174.4M (2031) at an 8.1% CAGR.
      • The UK's advanced healthcare infrastructure and NHS support drive strong demand for immunoglobulin and clotting factor therapies.
      • The UK's aging population and rising immunodeficiency prevalence create sustained market expansion opportunities through 2031.
      • The UK's regulatory environment and plasma self-sufficiency initiatives position it as a leading European plasma therapeutics hub.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      UK Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Pharmaceutical Manufacturers : UK-based and international plasma fractionation companies need market intelligence to guide product development, licensing strategies, and commercial expansion within the NHS and private healthcare sectors.
      • Healthcare Providers and NHS Trusts : Hospital procurement teams and clinical commissioning groups require market data to optimize plasma product sourcing, budget forecasting, and therapeutic protocol development for immunology and hematology departments.
      • Investment and Private Equity Firms : Investors evaluating UK healthcare opportunities need comprehensive market analysis to assess growth potential, identify acquisition targets, and evaluate returns in the plasma fractionation sector.
      • Regulatory and Policy Bodies : MHRA, NHS England, and health policy organizations utilize market insights to inform regulatory frameworks, reimbursement policies, and strategic planning for plasma-derived medicine availability.
      • Medical Device and Diagnostic Companies : Suppliers of plasma collection, testing, and fractionation equipment need UK market forecasts to align product development, sales strategies, and partnerships with healthcare infrastructure expansion.

      Reasons to Buy this Report

      • UK-Specific Market Sizing : Access precise valuation data for the UK plasma fractionation market with detailed 2026-2031 forecasts, enabling accurate budget allocation and investment decisions tailored to the British healthcare landscape.
      • Regulatory and Reimbursement Insights : Understand MHRA approval pathways, NHS commissioning frameworks, and NICE guidance specific to plasma-derived therapies, ensuring compliance and optimized market entry strategies for UK operations.
      • Competitive Landscape Analysis : Identify key UK market players, their market share, product portfolios, and strategic positioning within the immunoglobulin and clotting factor segments to inform competitive strategy.
      • Demographic and Clinical Trends : Leverage UK-specific epidemiological data on aging populations, immunodeficiency prevalence, and hemophilia incidence to forecast demand and identify high-growth therapeutic segments.
      • Supply Chain and Infrastructure Assessment : Evaluate UK plasma collection capacity, manufacturing capabilities, distribution networks, and domestic sourcing opportunities to optimize supply chain efficiency and reduce operational risks.

      Frequently asked questions

      What is the projected size of the UK plasma fractionation market by 2031?

      The UK plasma fractionation market is projected to reach USD 2,174.4 million by 2031, growing from USD 1,471.5 million in 2026.

      What is the CAGR for the UK plasma fractionation market?

      The UK plasma fractionation market is expected to grow at a compound annual growth rate (CAGR) of 8.1% between 2026 and 2031.

      What factors are driving growth in the UK plasma fractionation market?

      The UK market is driven by an aging population, rising immunodeficiency disorders, advanced healthcare infrastructure, NHS support, and favorable reimbursement policies.

      How does the UK regulatory environment support plasma fractionation market growth?

      The UK's regulatory framework supports innovation while ensuring product safety and efficacy, and the country's commitment to plasma self-sufficiency strengthens market stability.

      Which plasma-derived products are most in demand in the UK?

      Immunoglobulin therapies and clotting factor products are among the most in-demand plasma-derived products in the UK market.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status